Class Action Lawsuit Against MoonLake Immunotherapeutics Filed for Investor Losses

Investor Alert: Class Action Lawsuit Against MoonLake Immunotherapeutics

Investors in MoonLake Immunotherapeutics, a biopharmaceutical company trading under the NASDAQ ticker MLTX, have been alerted about a class action lawsuit filed by Bronstein, Gewirtz & Grossman, LLC. This prestigious law firm aims to enhance the rights of investors who have suffered significant financial losses.

Background of the Case

The class action arises from substantial allegations against MoonLake. The defendants in this case, including the company and its key officers, are accused of violating federal securities laws. Specifically, investors who acquired MoonLake securities between March 10, 2024, and September 29, 2025, could be part of this class action.

At the heart of the allegations is the claim that the company misrepresented the effectiveness of its drug candidate, sonelokimab (referred to as SLK). Plaintiffs argue that MoonLake falsely claimed that SLK was superior to other monoclonal antibodies without any evidence to substantiate these claims. Furthermore, the company reportedly marketed SLK's supposed advantages while intentionally omitting crucial information regarding its comparative performance. Analyst reports later revealed disappointing results from Phase 3 trials, which significantly impacted MoonLake's stock value, causing it to plummet by nearly 90%.

Class Period and Investors' Eligibility

The class action is designed to represent all individuals and entities affected by these alleged misrepresentations during the defined class period. Investors who feel they have incurred losses related to MoonLake’s misstatements are encouraged to take action by visiting Bronstein, Gewirtz & Grossman's dedicated page for this case. If you suffered losses in MoonLake, it's crucial to note that the deadline to request the court to appoint you as lead plaintiff is December 15, 2025.

Legal Representation with No Upfront Cost

One of the key selling points of this lawsuit is that the firm operates on a contingency fee basis. This means they will only recover their expenses and attorney fees from the case proceeds if they succeed in winning damages for investors. Consequently, this arrangement allows investors, concerned about the potential costs of legal action, to participate without the burden of added financial pressure.

What’s Next for Investors?

If you believe your investments in MoonLake have been adversely affected, now is the time to act. Collectively, shareholders may have the capacity to initiate a significant legal challenge against the company, holding them accountable for their alleged wrongdoings.

Bronstein, Gewirtz & Grossman, LLC has previously been recognized for their commitment to defending investors in similar class actions, having recovered hundreds of millions of dollars for clients. Investors can stay informed by following the firm’s progress and updates on platforms like LinkedIn and Facebook.

Understanding your rights as an affected investor is crucial. For more information, you may also reach out to Peretz Bronstein or Nathan Miller of the firm at the contact details provided on their website. Join forces with other investors to ensure that your voice and concerns are heard in this significant legal pursuit.

Stay vigilant and aware of the ongoing developments concerning MoonLake Immunotherapeutics. The outcome of this case may not only impact your investments but may also serve as a cautionary tale in the biotech sector about the importance of transparency and integrity in pharmaceutical claims.